1,5-distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the teatment of eye diseases such as glaucoma

Details for Australian Patent Application No. 2003233729 (hide)

Owner Merck Frosst Canada Ltd.

Inventors Han, Yongxin; Billot, Xavier; Young, Robert N.

Agent Spruson & Ferguson

Pub. Number AU-B-2003233729

PCT Number PCT/CA03/00838

PCT Pub. Number WO2003/103772

Priority 60/386,499 06.06.02 US; 60/460,134 03.04.03 US

Filing date 2 June 2003

Wipo publication date 22 December 2003

Acceptance publication date 4 October 2007

International Classifications

C07D 403/06 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

A61K 31/13 (2006.01) - Amines, e.g. amantadine

A61K 31/137 (2006.01) - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

A61K 31/138 (2006.01) - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine

A61K 31/382 (2006.01) - having six-membered rings, e.g. thioxanthenes

A61K 31/4015 (2006.01) - having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide

A61K 31/41 (2006.01) - having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole

A61K 31/416 (2006.01) - condensed with carbocyclic ring systems, e.g. indazole

A61K 31/4164 (2006.01) - 1,3-Diazoles

A61K 31/4168 (2006.01)

A61K 31/4178 (2006.01)

A61K 31/433 (2006.01) - Thiadiazoles

A61K 31/4412 (2006.01) - having oxo groups directly attached to the heterocyclic ring

A61K 31/498 (2006.01) - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine

A61K 31/5377 (2006.01)

A61K 31/5575 (2006.01)

A61K 31/559 (2006.01)

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 3/14 (2006.01) Drugs for disorders of the metabolism

A61P 19/00 (2006.01) Drugs for skeletal disorders

A61P 19/02 (2006.01) Drugs for skeletal disorders

A61P 19/08 Drugs for skeletal disorders

Event Publications

28 August 2003 Complete Application Filed

  Priority application(s): 60/386,499 06.06.02 US; 60/460,134 03.04.03 US

19 February 2004 Application Open to Public Inspection

  Published as AU-B-2003233729

16 March 2006 Assignment before Grant

  Merck Frosst Canada & Co. The application has been assigned to Merck Frosst Canada Ltd.

4 October 2007 Application Accepted

  Published as AU-B-2003233729

31 January 2008 Standard Patent Sealed

20 March 2008 Amendment Made

  The nature of the amendment is: Amend the invention title to read 1,5-distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the treatment of eye diseases such as glaucoma 2003235466 CV Therapeutics, Inc. The nature of the amendment is as shown in the statement(s) filed 15 Oct 2007

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003233730-STACKED PLATE HEAT EXCHANGER

2003233728-SYSTEM AND METHOD FOR INJECTING INK INTO AN APPLICATION